×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
PR Newswire
After the study wind down, Pulmatrix will bear no further financial responsibility for the development of PUR1900 and will receive 2% royalties...
1 month ago
Pulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternatives
MarketWatch
By Ben Glickman Pulmatrix will close a study of a potential treatment for a fungal lung infection as it prioritizes limiting cash burn and...
3 months ago
Pulmatrix shuts down study, explores sale - Boston Business Journal
The Business Journals
The Bedford company is shutting down a Phase 2b study for a fungal lung infection treatment, reducing its cash burn and looking into...
3 months ago
Pulmatrix CMO position eliminated, shifts to outsourced CMO model
Investing.com
Pulmatrix CMO position eliminated, shifts to outsourced CMO model ... © Reuters. ... In a strategic shift to an outsourced model, Pulmatrix Inc...
1 month ago
Pulmatrix submits IND application for PUR3100
Clinical Trials Arena
Pulmatrix Inc · View all. PUR3100 is an orally inhaled dihydroergotamine (DHE) formulated as dry powder and used with Pulmatrix's iSPERSE...
9 months ago
Pulmatrix Full Year 2023 Earnings: US$3.87 loss per share (vs US$5.46 loss in FY 2022)
Simply Wall Street
Pulmatrix ( NASDAQ:PULM ) Full Year 2023 Results Key Financial Results Revenue: US$7.30m (up 20% from FY 2022). Net...
1 month ago
Pulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.com
Defense World
Read Pulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.com at Defense World.
1 week ago
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement ...
PR Newswire
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve...
3 months ago
Pulmatrix Shifts to Outsourced CMO Model, Terminates Executive - TipRanks.com
Tipranks
Pulmatrix (PULM) has shared an announcement. Pulmatrix, Inc. has recently made a strategic shift by terminating its Chief Medical Officer,...
1 month ago
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 ...
ABC27
LEXINGTON, Mass., July 11, 2023 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage...
9 months ago